Recent Finacing
Recent Raise
Asgard Therapeutics is a preclinical-stage biotech developing TrojanDC, an off-the-shelf in vivo gene therapy that reprograms tumor cells into type-1 conventional dendritic cells for personalized antigen presentation.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Asgard Therapeutics.
